Cargando…
Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs)
Neuroendocrine tumors (NETs) are rare, heterogeneous, often indolent tumors that predominantly originate in the lungs and gastrointestinal tract. An understanding of the biology and tumor microenvironment of NETs has led to the development of molecularly targeted treatment options including somatost...
Autor principal: | Xu, Jianming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411625/ https://www.ncbi.nlm.nih.gov/pubmed/34484432 http://dx.doi.org/10.1177/17588359211042689 |
Ejemplares similares
-
The efficacy of oxaliplatin, surufatinib, and camrelizumab on neuroendocrine carcinoma: a case report and literature review
por: Wang, Xianhua, et al.
Publicado: (2022) -
Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies
por: Li, J., et al.
Publicado: (2022) -
Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis
por: Cai, Tianying, et al.
Publicado: (2023) -
Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
por: Uri, Inbal, et al.
Publicado: (2018) -
Surufatinib-induced renal thrombotic microangiopathy: first case report and review of literature
por: Zhu, Wenjiao, et al.
Publicado: (2023)